Almatica Drug Patent Portfolio

Almatica owns 3 orange book drugs protected by 12 US patents Given below is the list of Almatica's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8999393 Sustained release formulations of lorazepam 08 Jan, 2034
Active
US7776358 Extended release venlafaxine besylate tablets 16 May, 2028
Active
US7438927 Methods of treatment using a gastric retained gabapentin dosage 26 Feb, 2024 Expired
US6717015 Venlafaxine besylate 27 Mar, 2023 Expired
US7731989 Gastric retained gabapentin dosage form 25 Oct, 2022 Expired
US8192756 Gastric retained gabapentin dosage form 25 Oct, 2022 Expired
US8252332 Gastric retained gabapentin dosage form 25 Oct, 2022 Expired
US8333992 Gastric retained gabapentin dosage form 25 Oct, 2022 Expired
US6723340 Optimal polymer mixtures for gastric retentive tablets 25 Oct, 2021 Expired
US6488962 Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms 20 Jun, 2020 Expired
US6340475 Extending the duration of drug release within the stomach during the fed mode 19 Sep, 2016 Expired
US6635280 Extending the duration of drug release within the stomach during the fed mode 19 Sep, 2016 Expired


Given below is the list of recent legal activities going on the following drug patents of Almatica.

Activity Date Patent Number
Patent litigations
Expire Patent 08 Jul, 2024 US8192756
Maintenance Fee Reminder Mailed 15 Apr, 2024 US8252332
Maintenance Fee Reminder Mailed 22 Jan, 2024 US8192756
Payment of Maintenance Fee, 8th Year, Large Entity 21 Sep, 2022 US8999393
Expire Patent 11 Jul, 2022 US7731989
Payment of Maintenance Fee, 12th Year, Large Entity 02 Feb, 2022 US7776358
Maintenance Fee Reminder Mailed 24 Jan, 2022 US7731989
Payment of Maintenance Fee, 8th Year, Large Entity 18 Jun, 2020 US8333992
Payment of Maintenance Fee, 12th Year, Large Entity 21 Apr, 2020 US7438927
Payment of Maintenance Fee, 8th Year, Large Entity 28 Feb, 2020 US8252332
Payment of Maintenance Fee, 8th Yr, Small Entity 05 Dec, 2019 US8192756
Mail O.P. Petition Decision 25 Jun, 2019 US8999393
Email Notification 25 Jun, 2019 US8999393
Mail-Petition Decision - Dismissed 21 Jun, 2019 US8999393
O.P. Petition Decision 20 Jun, 2019 US8999393


Almatica's Drug Patent Litigations

Almatica's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Dec 31, 2008, against patent number US7776358. The petitioner , challenged the validity of this patent, with Joan Cucala Escoi et al as the respondent. Click below to track the latest information on how companies are challenging Almatica's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US6340475 April, 2014 Final Written Decision
(21 Sep, 2015)
Depomed, Inc. Endo Pharmaceutical Inc. et al.
US6635280 April, 2014 Final Written Decision
(21 Sep, 2015)
Depomed, Inc. Endo Pharmaceutical Inc. et al.
US6723340 April, 2014 Final Written Decision
(16 Sep, 2015)
DepoMed, Inc. Endo Pharmaceutical Inc. et al.
US6340475 January, 2014 FWD Entered
(08 Jul, 2015)
Depomed, Inc. Purdue Pharma L.P.
US6635280 January, 2014 FWD Entered
(08 Jul, 2015)
DepoMed, Inc. Purdue Pharma L.P.
US6340475 April, 2014 Institution Denied
(29 Sep, 2014)
Depomed, Inc. Endo Pharmaceutical Inc. et al.
US6635280 April, 2014 Institution Denied
(29 Sep, 2014)
Depomed, Inc. Endo Pharmaceutical Inc. et al.
US6723340 April, 2014 Institution Denied
(29 Sep, 2014)
DepoMed, Inc. Endo Pharmaceutical Inc. et al.
US7776358 December, 2008 Decision
(13 Feb, 2010)
Joan Cucala Escoi et al


Almatica Drug Patents' Oppositions Filed in EPO

Almatica drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 03, 2014, by Purdue Pharma Lp. This opposition was filed on patent number EP02781665A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP02781665A Jan, 2014 Purdue Pharma LP Patent maintained as amended


Almatica's Family Patents

Almatica drugs have patent protection in a total of 12 countries. It has a significant patent presence in the US with 55.9% of its patents being US patents. 7 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Almatica Drug List

Given below is the complete list of Almatica's drugs and the patents protecting them.


1. Gralise

Gralise is protected by 9 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7438927 Methods of treatment using a gastric retained gabapentin dosage 26 Feb, 2024
(7 months ago)
Expired
US7731989 Gastric retained gabapentin dosage form 25 Oct, 2022
(1 year, 11 months ago)
Expired
US8192756 Gastric retained gabapentin dosage form 25 Oct, 2022
(1 year, 11 months ago)
Expired
US8252332 Gastric retained gabapentin dosage form 25 Oct, 2022
(1 year, 11 months ago)
Expired
US8333992 Gastric retained gabapentin dosage form 25 Oct, 2022
(1 year, 11 months ago)
Expired
US6723340 Optimal polymer mixtures for gastric retentive tablets 25 Oct, 2021
(2 years ago)
Expired
US6488962 Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms 20 Jun, 2020
(4 years ago)
Expired
US6340475 Extending the duration of drug release within the stomach during the fed mode 19 Sep, 2016
(8 years ago)
Expired
US6635280 Extending the duration of drug release within the stomach during the fed mode 19 Sep, 2016
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gralise's drug page


2. Loreev Xr

Loreev Xr is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8999393 Sustained release formulations of lorazepam 08 Jan, 2034
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Loreev Xr's drug page


3. Venlafaxine Besylate

Venlafaxine Besylate is protected by 2 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7776358 Extended release venlafaxine besylate tablets 16 May, 2028
(3 years from now)
Active
US6717015 Venlafaxine besylate 27 Mar, 2023
(1 year, 6 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Venlafaxine Besylate's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List